WHO Guidelines development group meeting for the treatment of HAT
Date: 3-4 December 2018
Venue: WHO Headquarters, Geneva
The meeting will discuss the new WHO Interim Guidelines for the Treatment of Human African Trypanosomiasis.
Fexinidazole, which recently emerged from clinical research and which is expected to receive regulatory approval soon, will be included.
Fexinidazole, as a new therapeutic tool, has specific advantages and disadvantages.
WHO will issue guidelines that aim to integrate Fexinidazole within the current therapeutic arsenal to achieve optimal management of HAT cases.